The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

July 31, 2029

Study Completion Date

July 31, 2029

Conditions
PSP - Progressive Supranuclear Palsy
Interventions
BIOLOGICAL

AADvac1

AADvac1 administration: subcutaneous injection.

BIOLOGICAL

Matching Placebo

Matching placebo administration: subcutaneous injection.

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

Alzheimer's Therapeutic Research Institute

OTHER

collaborator

University of Southern California

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

University of California, San Diego

OTHER

collaborator

Alzheimer's Clinical Trials Consortium

OTHER

collaborator

Axon Neuroscience SE

INDUSTRY

lead

Adam Boxer

OTHER

NCT07217665 - The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1 | Biotech Hunter | Biotech Hunter